ORAGENICS INC — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Oragenics CMO Dr. James P. Kelly will present at IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026, discussing ONP-002 development and clinical translation. The presentation will cover the Phase IIa feasibility trial ongoing in Australia and anticipated U.S. IND submission in Q4 2026. No financial transactions, partnerships, or material corporate developments are disclosed.
Why this rating
Conference presentation of existing clinical program. No deal, funding, partnership, or trial outcome disclosed. Routine investor communications for $3.1M market-cap biotech.
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.